1、Novartis in SocietyESG Report 20192|Novartis in SocietyContents2019 highlights 3Who we are 4What we do 6Message from the CEO 8Global Health&Corporate Responsibility at Novartis 9Strategic areas 13Holding ourselves to the highest ethical standards 13Being part of the solution onpricing and access 20A
2、ddressing global healthchallenges 32Being a responsible citizen 39About this report 50Performance indicators 2019 51Novartis GRI Content Index 55Appendix:corporate responsibility material topic boundaries 59Appendix:corporate responsibility materiality assessment issue cluster andtopic definitions 6
3、1Appendix:external initiatives and membership of associations 63Appendix:supplier spend 2019 64Appendix:the responsible procurement(RP)risk indicator tool 64Appendix:measuring and valuing our impact 65Independent Assurance Report onthe 2019 Novartis in Society ESGreporting 66Cover photo Patients at
4、Kumasi General Hospital in Ghana,where newborns are screened for sickle cell disease.Only about 4%of babies in Ghana are tested for this debilitating genetic blood disorder.Photo A worker at Ziplines distribution center in Omenako,Ghana,prepares a medical order for drone delivery.Novartis has partne
5、red with Zipline,a US-based automated logistics company,to help deliver vital medicines to remote areas.Novartis in Society|32019 hiGhliGhtS2019 highlights99/100SCOREachieved by Novartis for clinical trial transparency in a recent analysis published by BMJ500+ASSOCIATESvolunteered to be part of the
6、networkthat will create the NovartisCode of Ethics135 HIGH-LEVEL AUDITSperformed on 100%of suppliers with active follow-up16mPATIENTSreached through access programs 10m+PEOPLEreached through training and health education programs 300 000+PATIENTSreached with over 90 local brands for some of our most